Corcept Therapeutics (CORT) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Corcept Therapeutics faces a significant business risk following its Board of Directors’ decision in January 2024 to authorize a stock repurchase program of up to $200 million. This program, while discretionary in the number of shares to be repurchased, could deplete the company’s cash reserves, potentially limiting its financial agility. The repurchase strategy may preclude more beneficial capital investments and inadvertently constrain Corcept’s ability to respond to unforeseen capital needs or to capitalize on emergent opportunities, thereby affecting its long-term financial stability and growth prospects.
The average CORT stock price target is $39.50, implying 73.93% upside potential.
To learn more about Corcept Therapeutics’ risk factors, click here.
